DexCom Q4 Preliminary Revenue Improves; Pre-Market Stock Up

DexCom

78.64 CHF 9.68%

• Charts
• News
• Analysen

Kaufen / Verkaufen

(RTTNews) - DexCom, Inc. (DXCM), a maker of continuous glucose monitoring systems for diabetes management, on Monday reported a rise in preliminary revenue for the fourth quarter. For the fourth quarter, the company reported preliminary revenue of at least $1.113 billion, up 8 percent from the same period last year. The U.S. revenue is expected to be approximately $803 million, representing a year-on-year growth of 4 percent.

For the full-year 2024, preliminary revenue stood at approximately $4.032 billion, an increase of 11 percent over 2023.

Kevin Sayer, CEO of DexCom, said: "Dexcom made key strategic investments in 2024 that steadily progressed throughout the year, leaving us well positioned to capitalize on our growth opportunity ahead. We plan to build on these investments in 2025 by further enhancing our differentiated product portfolio and advocating for greater CGM access globally."

Looking ahead, for the full-year 2025, Dexcom currently anticipates revenue of $4.60 billion, representing a growth of approximately 14 percent over 2024. This guidance considers sensor volume growth driven by increasing CGM access and awareness for people with diabetes, the continued rollout of Stelo, further international expansion, and overall market dynamics.

Dexcom will release its annual earnings report on February 13.

DXCM was up by 5.47 percent at $82.01 in the pre-market trade on the Nasdaq.